A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 25 shares of EXAS stock, worth $1,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25
Previous 452 94.47%
Holding current value
$1,660
Previous $31,000 96.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$41.33 - $74.26 $17,647 - $31,709
-427 Reduced 94.47%
25 $1,000
Q1 2024

Apr 29, 2024

BUY
$56.27 - $73.77 $10,072 - $13,204
179 Added 65.57%
452 $31,000
Q4 2023

Feb 06, 2024

BUY
$59.06 - $75.72 $14,646 - $18,778
248 Added 992.0%
273 $20,000
Q3 2022

Oct 28, 2022

SELL
$31.97 - $49.37 $639 - $987
-20 Reduced 44.44%
25 $1,000
Q1 2022

May 04, 2022

SELL
$57.56 - $82.54 $1,151 - $1,650
-20 Reduced 30.77%
45 $3,000
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $7,577 - $10,075
65 New
65 $9,000
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $26,202 - $43,592
-470 Closed
0 $0
Q1 2020

May 07, 2020

BUY
$37.9 - $104.44 $17,813 - $49,086
470 New
470 $27,000
Q3 2019

Nov 05, 2019

SELL
$90.37 - $122.49 $2,439 - $3,307
-27 Closed
0 $0
Q2 2019

Aug 08, 2019

BUY
$89.51 - $118.04 $2,416 - $3,187
27 New
27 $3,000
Q4 2018

Jan 31, 2019

SELL
$56.04 - $82.66 $1,737 - $2,562
-31 Closed
0 $0
Q2 2018

Jul 19, 2018

BUY
$37.84 - $69.96 $416 - $769
11 Added 55.0%
31 $2,000
Q1 2018

Apr 17, 2018

BUY
$39.82 - $57.53 $796 - $1,150
20 New
20 $1,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $11.8B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.